1988
Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities. Blood 1988, 71: 403-414. DOI: 10.1182/blood.v71.2.403.403.Peer-Reviewed Original ResearchCytogenetic studiesChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7De novo leukemiaAbstract Cytogenetic studiesCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapyCytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1980
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities